Israeli medical cannabis company Cannabotech is investigating how different combinations of cannabinoids, plants, and fungi can treat a variety of diseases. They are currently targeting a pill containing cannabinoids and active substances in mushrooms. There are even studies that investigate if psychedelic fungi treat anorexia. Researchers are also looking to get patients out of comas.
In the past, the idea of combining cannabis and mushrooms could only come from drug dealers. Currently, this plan is the most normal thing in the world for a new, growing movement of pharmacists.
An emerging player in this sector is Cannabotech from Israel with a movement that uses natural plants and fungi to treat diseases, especially diseases that react badly to regular drugs.
The Hemp.im application organizes what’s happening in the cannabis world to help you learn more about the stories that matter to you. Stay informed with the latest hemp news and get the important information in one application.
Cannabotech is a pharmaceutical startup that develops cannabinoid-based healthcare products. Thus, the company’s primary focus is on the beneficial properties of cannabis.
“Each cannabis plant has 30 to 40 cannabinoids that are active in the body. There are several hundred in total,” said Cannabotech co-founder and CEO Elchanan Shaked. “We believe the secret of the plant’s activity lies in cannabinoids, which occur in small amounts. If you change the relationships between them and increase their concentration in the final product, a very high medical effectiveness for the treatment of various diseases can be created.”
Many people see the future of medical cannabis in the manual composition of different cannabinoid profiles.
Currently, a lot of research is being done on two cannabinoids that are most common in the plant: THC and CBD. But Shaked pointed out that there are many more cannabinoids, each with their own beneficial properties.
Once the action of all those cannabinoids has been figured out, science can look for specific combinations that work optimally for certain conditions. Cannabotech is fully committed to this.
The company wants to show that manually selected cannabinoid ratios are more effective than the ratios in naturally grown plants. But that’s not the only thing the company is focusing on.
Cannabotech goes a step further by combining the active ingredients from mushrooms and other plants and fungi with cannabinoids. To date, the company has developed five specific cannabis and mushroom blends to treat colorectal cancer, infertility, fatty liver, inflammation, and cardiovascular disease. These products are all currently awaiting clinical trials.
“Penicillin comes from a fungus,” explained Shaked. “The benefits of mushrooms and other fungi have been studied for thousands of years.”
Prof. Solomon Wasser has been researching cannabis and mushrooms at the University of Haifa for decades. He has huge libraries of mushroom ingredients and information on treatment, along with other ingredients.
So far, Cannabotech is limited to non-psychedelic components from mushrooms and fungi. This is remarkable because a growing number of studies prove that psilocybin is very effective in mental disorders.
Recent studies showed that psilocybin helps to overcome treatment-resistant depression, alcoholism, and anxiety.
There are even studies that look at whether psychedelic fungi treat anorexia. Researchers are also looking for ways to get patients out of comas with cannabis and mushrooms.
These studies are so serious that the U.S. Food and Drug Administration is conducting clinical trials. They will probably lead to the legalization of psychotherapy with psilocybin in the coming years.
__
(Featured image by Ahmed Zayan via Unsplash)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Mediwietsite, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Ontario is investing $31 million over the next three years to enhance efforts against illegal…
Frankfurt and Hanover are launching five-year pilot projects for legal, regulated cannabis sales to adults,…
Italy's Regional Administrative Court suspended the Health Ministry's decree labeling CBD as a narcotic, pending…
This November, five U.S. states will vote on measures related to legalizing recreational or medical…
The European Commission has launched an investigation into Italy after its recent proposal to ban…
A new study has found that prolonged use of high-THC cannabis leaves a unique mark…